BELLICUM PHARMACEUTICALS INC's ticker is and the CUSIP is 079481404. A total of 31 filers reported holding BELLICUM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $14,869 | -54.2% | 45,057 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $32,441 | -39.9% | 45,057 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $54,000 | -8.5% | 45,057 | -9.5% | 0.00% | -50.0% |
| Q2 2022 | $59,000 | -45.4% | 49,797 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $108,000 | +45.9% | 49,797 | 0.0% | 0.00% | +50.0% |
| Q4 2021 | $74,000 | -49.0% | 49,797 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $145,000 | -17.1% | 49,797 | -6.1% | 0.00% | -33.3% |
| Q2 2021 | $175,000 | -12.1% | 53,041 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $199,000 | +6.4% | 53,041 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $187,000 | – | 53,041 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 159,500 | $563,000 | 0.11% |
| Ikarian Capital, LLC | 500,000 | $1,765,000 | 0.08% |
| Anson Funds Management LP | 99,103 | $350,000 | 0.07% |
| GSA CAPITAL PARTNERS LLP | 66,558 | $235,000 | 0.04% |
| AJU IB Investment Co., Ltd. | 25,651 | $91,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 53,041 | $187,000 | 0.01% |
| SHUFRO ROSE & CO LLC | 12,941 | $46,000 | 0.00% |
| Baker Brothers Advisors | 249,123 | $879,000 | 0.00% |
| Tekla Capital Management LLC | 6,000 | $21,000 | 0.00% |
| Orion Capital Management LLC | 500 | $2,000 | 0.00% |